Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results (PR Newswire, 10 May 2013)

A Phase III trial of Lexicon’s Telotristat etiprate (LX1032) in carcinoid syndrome is currently recruiting participants.

The 12-week double-blind TELESTAR (Telotristat Etiprate for Somatostatin Analogue Refractory Carcinoid Syndrome) study will assess the tryptophan hydroxylase inhibitor’s efficacy in reducing the change from baseline in the number of daily bowel movements. UK study sites comprise Basingstoke and London.

Telotristat etiprate has received Fast Track designation from the US Food and Drug Administration (FDA) and orphan drug designation from both the FDA and the European Medicines Agency, conferring a number of privileges in the approval process and market exclusivity for drugs for rare conditions that meet unmet medical needs.

Source: PR Newswire

TELESTAR trial at ClinicalTrials.gov